All In Biotech

Drug Trial Radar · NCT01285765

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+

Last checked: Nov 20, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

650

Actual

Start

Dec 2010

Primary completion

May 23, 2020

Study completion May 23, 2020

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Central Hospital, Nancy, France
First posted
Jan 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the investigators purpose is to evaluate the adaptation of treatment with early response based on PET scan results after 2 cycles of chemotherapy, for patient aged from 18 to 80 years, with low IPI DLBCL. This is an open randomized study. The primary endpoint is to evaluate the 3 years PFS with the aim to demonstrate the non inferiority of the experimental arm in comparison to standard arm: In standard arm, the patients will receive 6 cycles of R-CHOP 21 without taking into account of PET scan results after 2 cycles. In experimental arm, early good responder patients (defined as having a negative PET scan after 2 cycles, confirmed after 4 cycles) will receive only 4 cycles of R-CHOP 21. In both arms, if the PET scan remains positive after 4 cycles of chemotherapy, a biopsy exam is needed to confirm the failure and an intensive chemotherapy is then recommended. All of the patients, in both arms, will have an early evaluation with PET scan. All PET scan will be reviewed by a group of expert according to Deauville criteria defined by Meignan et al to adapt the decision after the 2nd cycle in experimental arm and after the 4th cycle for all patients. The final evaluation of response will be made according to 2007 Cheson's criteria.

Conditions

  • DLBCL

Interventions

  • RCHOP21Drug

    Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 3 years

Locations

83 sites in 2 countries. Site status is shown where the registry gives one.

  • ZNA Stuivenberg

    Antwerp, Belgium

  • A. Z. Sint-Jan

    Bruges, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Université Libre de Bruxelles - Hôpital Erasme

    Brussels, Belgium

  • Université Catholique de Louvain Saint Luc

    Brussels, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • UZ Gent

    Ghent, Belgium

  • Hôpital Jolimont

    Haine-Saint-Paul, Belgium

  • CHU de Liège

    Liège, Belgium

  • Clinique Saint Joseph

    Mons, Belgium

  • Clinique Saint Pierre

    Ottignies, Belgium

  • Centre Hospitalier de Wallonie Picarde - CHwapi

    Tournai, Belgium

  • CH de la Tourelle-Peltzer

    Verviers, Belgium

  • UCL Mont Godinne

    Yvoir, Belgium

  • CHU Angers

    Angers, France

  • Centre Hospitalier Victor Dupouy

    Argenteuil, France

  • CH d'ARRAS

    Arras, France

  • CH d'Avignon

    Avignon, France

  • CH de la Côte Basque

    Bayonne, France

  • CHU de Besançon - Hôpital Jean Minjoz

    Besançon, France

  • Institut Bergonié - Bordeaux

    Bordeaux, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, France

  • CH du Dr Duchenne

    Boulogne-sur-Mer, France

  • CH de Bourg-en-Bresse

    Bourg-en-Bresse, France

  • IHBN - CHU Côte de Nacre

    Caen, France

  • CH de Cannes

    Cannes, France

  • Médipôle de Savoie

    Challes-les-Eaux, France

  • Hôpital de Chalon

    Chalon-sur-Saône, France

  • CH de Chambéry

    Chambéry, France

  • Hôpital d'Instruction des Armées Percy

    Clamart, France

  • CHU Estaing - Clermont Ferrand

    Clermont-Ferrand, France

  • Hôpital Pasteur

    Colmar, France

  • CH de Compiègne

    Compiègne, France

  • Centre Hospitalier Alpes Léman

    Contamine-sur-Arve, France

  • CH Sud Francilien

    Corbeil-Essonnes, France

  • Hôpital Henri MONDOR

    Créteil, France

  • Chu Dijon

    Dijon, France

  • CH de Dunkerque

    Dunkirk, France

  • CHU de Grenoble - Hôpital Albert Michallon

    Grenoble, France

  • CH Départemental Vendée

    La Roche-sur-Yon, France

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.